急性淋巴细胞白血病患者单倍体相合与相合无关供者移植:供者年龄比供者类型更重要
该研究比较成人急性淋巴细胞白血病(ALL)患者中供者年龄(<35岁 vs ≥35岁)和供者类型(单倍体相合 vs 相合无关供者MUD)对总生存(OS)的影响,发现供者年龄较大与OS显著较差独立相关,而供者类型不是独立因素;在年轻单倍体相合供者与年长MUD的对比中,年长MUD组慢性GVHD、非复发死亡(NRM)更高、复发更低、OS更差。
要点
- 供者年龄≥35岁与ALL患者造血干细胞移植后OS显著较差独立相关,而供者类型与OS无关。
- 年轻单倍体相合供者联合移植后环磷酰胺(PTCy)预防GVHD较年长MUD联合传统预防的NRM更低、OS更好。
- 年长MUD组慢性GVHD风险更高、NRM更高、复发更低,但OS仍更差。
核心结论
- 供者年龄较大(≥35岁)与ALL成人患者HCT后OS显著较差独立相关,而供者类型(单倍体相合 vs MUD)不是独立因素。
- 年轻单倍体相合供者联合PTCy预防较年长MUD联合传统预防的NRM更低、OS更好,尽管年轻单倍体相合组复发风险更高,作者认为前者可能更优。
- 需要进一步分析比较单倍体相合PTCy与MUD PTCy中供者年龄的影响。
研究设计与样本
- 研究纳入成人ALL患者,比较供者年龄(<35岁 n=868 vs ≥35岁 n=418)和供者类型(单倍体相合 n=373 vs MUD n=913)对OS的影响。
- 进一步直接比较年轻单倍体相合供者(n=187)与年长MUD(n=232)的移植结局。
主要发现
- 多因素分析显示,年长MUD组较年轻单倍体相合组慢性GVHD风险更高、NRM更高、复发更低、OS更差。
- 年轻单倍体相合组较年长MUD组,B细胞免疫表型比例更高(89% vs 77%,P<.001),接受骨髓移植物比例更高(42% vs 16%,P<.001),接受减低强度预处理比例更高(45% vs 23%,P<.001)。
- 年轻单倍体相合组与年长MUD组在不良细胞遗传学(61% vs 51%,P=.44)和费城染色体阴性(53% vs 48%,P=.38)方面无显著差异。
临床怎么用
- 作者认为,在ALL患者中,尽管年轻单倍体相合供者联合PTCy预防的复发风险更高,但因NRM更低和OS更好,可能优于年长MUD联合传统预防。
- 原文未据此给出其他推荐。
局限性
- 需要进一步分析比较单倍体相合PTCy与MUD PTCy中供者年龄的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haploidentical hematopoietic cell transplantation (HCT) with posttransplant cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis yields a similar overall survival (OS) to HLA-matched unrelated donor (MUD) HCT with conventional prophylaxis. Given the prognostic implications of donor age, we investigated the impact of donor age (younger [<35 years, n = 868] vs older [≥35 years, n = 418]) and donor type (haploidentical [n = 373] vs MUD [n = 913]) on OS in adult patients with acute lymphoblastic leukemia (ALL). Older donor age was independently associated with significantly poor OS, whereas donor type was not. Next, we directly compared the outcomes of a younger haploidentical donor (n = 187) vs an older MUD (n = 232). In this cohort, more patients in the haploidentical group had B-cell immunophenotype (89% vs 77%, respectively, P < .001), poor cytogenetics (61% vs 51%, respectively, P = .44), Philadelphia chromosome-negative (53% vs 48%, respectively, P = .38), received bone marrow graft (42% vs 16%, respectively, P < .001), and reduced-intensity conditioning (45% vs 23%, respectively, P < .001). In the multivariate analysis, the older MUD group was associated with a significantly higher risk of chronic GVHD, higher nonrelapse mortality (NRM), lower relapse, and poorer OS. Despite a higher risk of relapse, younger donor haploidentical HCT with PTCy prophylaxis may be preferred over older MUD HCT with conventional prophylaxis in patients with ALL due to lower NRM and better OS. Further analysis comparing the effect of donor age in haploidentical PTCy vs MUD PTCy is warranted.
引用
- Mehta RS, Marin D, Alousi A, et al. Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. Blood Adv. 2023. PMID: 36630564. doi:10.1182/bloodadvances.2022009240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。